Femasys’ (FEMY) “Buy” Rating Reaffirmed at HC Wainwright

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $15.00 price target on the stock.

Femasys Price Performance

Shares of NASDAQ FEMY opened at $1.34 on Friday. The company has a quick ratio of 3.26, a current ratio of 3.94 and a debt-to-equity ratio of 0.86. The stock’s 50-day simple moving average is $1.40 and its two-hundred day simple moving average is $1.22. The firm has a market capitalization of $30.57 million, a P/E ratio of -1.65 and a beta of -2.85. Femasys has a twelve month low of $0.86 and a twelve month high of $1.84.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.02. The firm had revenue of $0.58 million for the quarter, compared to analyst estimates of $1.66 million. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. As a group, equities analysts anticipate that Femasys will post -0.86 EPS for the current fiscal year.

Institutional Trading of Femasys

A number of institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC purchased a new stake in Femasys during the 4th quarter valued at $45,000. Jane Street Group LLC purchased a new position in Femasys during the 4th quarter valued at about $30,000. Northern Trust Corp raised its position in Femasys by 42.6% during the 4th quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock valued at $139,000 after purchasing an additional 37,675 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Femasys by 4.7% in the 4th quarter. Geode Capital Management LLC now owns 216,164 shares of the company’s stock worth $238,000 after buying an additional 9,681 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Femasys in the 4th quarter worth approximately $25,000. Hedge funds and other institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.